Navigation Links
GeoVax Phase 2a Clinical Trial Completes Enrollment
Date:10/3/2011

orm of the HIV envelope protein can elicit neutralizing Ab for tier 2 viruses."

"The completion of enrollment for our phase 2a trial is an important milestone," said Robert  McNally, Ph.D., GeoVax's President and CEO. "We now look forward to completion of the inoculations and the unblinding of safety and immunogenicity results for the entire trial."

Patient enrollment for HVTN 205 was conducted at 11 clinical sites in North America and two sites in South America.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of Phase 2 testing and the extension of clinical testing to include a granulocyte macrophage-colony stimulating factor (GM-CSF) adjuvanted version of the vaccine.  GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

About the HVTN

The HIV Vaccine Trials Network (HVTN) is the largest worldwide clinical trials network dedicated to the d
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
2. GeoVax Labs, Inc. Announces Second Quarter Financial Results
3. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
4. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
5. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
6. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
7. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
8. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
9. GeoVax Labs Engages The Investor Relations Group
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
11. GeoVax Labs, Inc. Plans Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... President and Chief Executive Officer of Neurocrine Biosciences, will be ... Health Care Conference in Boston.   The live ... Eastern Time / 8:20 a.m. Pacific Time.  The presentation will ... at http://www.neurocrine.com . If you are ...
(Date:5/23/2013)... THOUSAND OAKS, Calif. , May 23, 2013 ... Deutsche Bank 38 th Annual  Healthcare Conference on Thursday, ... Boston , beginning at 9:20 a.m. Eastern Daylight ... Investor Relations at Amgen, will present at the conference. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Aug. 2, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... completion of a clinical study that measured lorcaserin concentrations in ... The study was conducted to provide additional data that may ... of brain astrocytoma in male rats. Using the results of ...
... 2011 SI-BONE, Inc. (San Jose, California), a medical device ... joint, announced today that it is launching an intensive clinical ... initiative to generate a substantial body of clinical and economic ... this effort is MISSION ( M inimally I nvasive ...
Cached Medicine Technology:Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 2Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 3Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 4Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 5Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 6SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 2SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 3SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 4
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... Transvaginal mesh lawsuit claims ... move forward in a federal multidistrict litigation underway in ... Liebhard LLP reports. In an Order issued on ... Bard to seal emails that included supplier information the ... proprietary information about its suppliers. The emails were filed ...
(Date:5/23/2013)... 2013 The vast majority of Americans ... control over their level of physical activity, the healthfulness ... are actually taking that control. Those are among ... Foundation’s 2013 Food & Health Survey. , According to ... to have “a great deal of control” or “complete ...
(Date:5/23/2013)... On April 29th, 2013, UV Technologies ... of H7N9 cases and deaths. The headline read, " UV ... Subside in Northern Hemisphere as Available Daylight Increases .” In ... reported. , Quoting Kevin McGuire, president of UV Technologies, ... budding in the spring and leaves changing in the fall. ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul ... at stadiums throughout North America. This well known ticket ... concert tickets to help McCartney fans see Sir Paul live ... states that she is also offering the customer appreciation code ... a baby boomer, she is also a huge McCartney fan ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2
... Journal of Clinical Dentistry Demonstrate, Significant Cavity-Fighting ... N.Y. and STONY BROOK, N.Y., April 8, 2008 ... announced today that,new data published in the most ... the effects of a new chewable mint in ...
... Three-year demonstration project will test effectiveness of ... of chronic illness in the,Medicare population, ... Board: HFIT) announced today it is working ... of Pfizer Inc., as part of a,three-year ...
... Huckabee Share Behavior Change Successes ... and Discuss Healthcare Strategies and Trends, PALM SPRINGS, ... in scalable behavior change interventions with outcomes,kicked off ENGAGE ... 250 industry experts and leading employers and health plans,throughout ...
... be the greatest advance in waking up since coffee, ... wake up,in the morning feeling refreshed and ready to go, ... performance to spousal,relations and even driving ability. Fortunately, a unique ... a pill you take before,bedtime that will help you to ...
... 2008 Take a look in your,medicine cabinet ... so, are,you contributing to the nation,s dramatic increase ... National Drug Control,Strategies Report, 71 percent of prescription ... friends. Among 12- to 13-year-olds,prescription drug abuse actually ...
... The appearance of a cold sore is,a sign ... more serious,illnesses emerge, according to John Sherman, ND, noted ... Worldwide, between 80% and 90% of the adult population ... according to Dr. Sherman, who,is the author of The ...
Cached Medicine News:Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 2Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 3Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 4Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 3Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 4Health News:HealthMedia Kicks Off ENGAGE Conference 2Health News:HealthMedia Kicks Off ENGAGE Conference 3Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Prescription Drug Abuse Threatens Availability of Pain Medication 2Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2